CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Recent approvals of potentially pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment Opportunities for Berubicin to be used in additional oncology indications with significant unmet needs HOUSTON, May 16, 2022 /PRNewswire/ — CNS…

About the Author

has written 41611 stories on this site.

Copyright © 2010 Business and Corporate News.